Use of palivizumab and infection control measures to control an outbreak of respiratory syncytial virus in a neonatal intensive care unit confirmed by real-time polymerase chain reaction

J Hosp Infect. 2011 Apr;77(4):338-42. doi: 10.1016/j.jhin.2010.12.012. Epub 2011 Feb 16.

Abstract

Respiratory syncytial virus (RSV) is a potentially life-threatening infection in premature infants. We report an outbreak involving four infants in the neonatal intensive care unit (NICU) of our hospital that occurred in February 2010. RSV A infection was confirmed by real-time polymerase chain reaction. Palivizumab was administered to all infants in the NICU. There were no additional symptomatic cases and repeat RSV surveillance confirmed that there was no further cross-transmission within the unit. The outbreak highlighted the infection control challenge of very high bed occupancy in the unit and the usefulness of molecular methods in facilitating detection and management.

Publication types

  • Case Reports

MeSH terms

  • Antibodies, Monoclonal / administration & dosage*
  • Antibodies, Monoclonal, Humanized
  • Antiviral Agents / administration & dosage*
  • Cross Infection / drug therapy
  • Cross Infection / epidemiology*
  • Cross Infection / prevention & control
  • DNA, Viral / genetics
  • DNA, Viral / isolation & purification
  • Disease Outbreaks*
  • Female
  • Genotype
  • Humans
  • Infant
  • Infant, Newborn
  • Infection Control / methods
  • Intensive Care, Neonatal
  • Palivizumab
  • Polymerase Chain Reaction
  • Respiratory Syncytial Virus Infections / drug therapy
  • Respiratory Syncytial Virus Infections / epidemiology*
  • Respiratory Syncytial Virus Infections / prevention & control
  • Respiratory Syncytial Virus, Human / classification
  • Respiratory Syncytial Virus, Human / drug effects
  • Respiratory Syncytial Virus, Human / genetics
  • Respiratory Syncytial Virus, Human / isolation & purification*

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antiviral Agents
  • DNA, Viral
  • Palivizumab